Results of MIME salvage regimen for recurrent or refractory lymphoma

J Clin Oncol. 1987 Mar;5(3):407-12. doi: 10.1200/JCO.1987.5.3.407.


Based on encouraging results of two previous ifosfamide-VP-16 salvage combinations, methyl-gag was added to ifosfamide, methotrexate, and etoposide (VP-16). This combination is called MIME. A total of 208 patients with recurrent lymphoma were treated with this regimen. Response rates were 24% for complete remission and 36% for partial remission. The MIME regimen was more effective in patients who were treated after being off front-line therapy for longer than 6 months. However, responses were also seen in patients with disease clearly resistant to front-line therapy, suggesting that MIME was at least partially non-cross-resistant with front-line doxorubicin-containing regimens. The 15-month median relapse-free survival of complete responders and the 9-month overall median survival time for all patients treated were both similar to results from previous ifosfamide-VP-16 combination use. This regimen has been effective in the treatment of patients with recurrent or refractory lymphoma, but cannot be considered curative in the majority of cases.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Drug Resistance
  • Etoposide / administration & dosage
  • Humans
  • Ifosfamide / administration & dosage
  • Lymphoma / drug therapy*
  • Lymphoma / pathology
  • Methotrexate / administration & dosage
  • Mitoguazone / administration & dosage
  • Prognosis
  • Remission Induction


  • Etoposide
  • Mitoguazone
  • Ifosfamide
  • Methotrexate

Supplementary concepts

  • MIME protocol